 survival patients massive lymphadenopathy prostate cancer evidence heterogeneous tumour behaviour survival patients prostate cancer detectable lymph node enlargement period tomography patients symptoms signs biochemical results lymphatic spread pelvic abdominal node masses patients masses cm maximum node diameter cm Two-thirds patients tumour stage treatment actuarial survival patients nodal enlargement years group survival patients lymphadenopathy negative bone scans diagnosis patients node bone disease vs years improvement apparent inability certain tumours seed bone marked sensitivity node hormonal manipulation Primary tumour grade similar groups patients combined disease complete remission treatment reason heterogeneous biological behaviour unclear observations importance vigorous treatment patients advanced lymph node disease